Evidence map›Paper›PMID 42284420›Full record

ArticleScience advances2026

Gonzalo Rodriguez-Berriguete, Purusotha Thambiayah, Alessandro Cicconi, Nicole Machado, Celia Gotorbe, David Nderitu, Wei-Chen Cheng, Gerissa Fowler, Marie Laure Boursier, Aurora Cerutti and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Gonzalo Rodriguez-BerrigueteDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0003-1613-0291
Purusotha ThambiayahDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-3317-3237
Alessandro CicconiArtios Pharma, Babraham Research Campus, Cambridge, UK.ORCID 0000-0001-8248-3568
Nicole MachadoDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-8168-3493
Celia GotorbeDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0009-0003-1697-335X
David NderituDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0009-0000-5021-3774
Wei-Chen ChengDepartment of Oncology, University of Oxford, Oxford, UK.
Gerissa FowlerDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0001-9801-2613
Marie Laure BoursierArtios Pharma, Babraham Research Campus, Cambridge, UK.ORCID 0000-0003-1899-7323
Aurora CeruttiArtios Pharma, Babraham Research Campus, Cambridge, UK.
Vera GrinkevichArtios Pharma, Babraham Research Campus, Cambridge, UK.
Bethany Rebekah HillArtios Pharma, Babraham Research Campus, Cambridge, UK.
Katjuša KolerArtios Pharma, Babraham Research Campus, Cambridge, UK.ORCID 0000-0001-8624-9488
Sophie Alice LangdonArtios Pharma, Babraham Research Campus, Cambridge, UK.ORCID 0000-0002-8269-9606
Jayesh B MajithiyaArtios Pharma, Babraham Research Campus, Cambridge, UK.ORCID 0000-0003-2944-4871
Suraj MenonArtios Pharma, Babraham Research Campus, Cambridge, UK.
Shaun MooreArtios Pharma, Babraham Research Campus, Cambridge, UK.
Joana NevesArtios Pharma, Babraham Research Campus, Cambridge, UK.ORCID 0000-0002-9340-1086
Natalie M Palmer-DeverillArtios Pharma, Babraham Research Campus, Cambridge, UK.
Eeson RajendraArtios Pharma, Babraham Research Campus, Cambridge, UK.ORCID 0000-0002-5301-054X
Marina Roy-LuzarragaArtios Pharma, Babraham Research Campus, Cambridge, UK.
Asmita ThapaArtios Pharma, Babraham Research Campus, Cambridge, UK.
Robert A HealdArtios Pharma, Babraham Research Campus, Cambridge, UK.ORCID 0000-0003-3425-7130
Graeme C M SmithArtios Pharma, Babraham Research Campus, Cambridge, UK.ORCID 0000-0001-8320-4057
Helen M R RobinsonArtios Pharma, Babraham Research Campus, Cambridge, UK.ORCID 0000-0003-0414-0740
Marco RanzaniArtios Pharma, Babraham Research Campus, Cambridge, UK.ORCID 0000-0003-4253-3617
Geoff S HigginsDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0003-3072-909X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibition of DNA polymerase theta (Polθ), an essential enzyme for repairing DNA double-strand breaks (DSBs) via microhomology-mediated end joining (MMEJ), has proven to be an exquisitely effective monotherapy in HR-deficient tumor models. In addition, Polθ inhibition (Polθi) can induce tumor-selective radiosensitization, but unlike its monotherapy use, no clinically actionable biomarkers have yet been identified to predict this effect. Here, we profiled 54 cancer cell lines and found that Polθi induces substantial radiosensitization in most models, although with marked variability not explained by indicators of Polθ activity. To pinpoint molecular determinants of radiosensitization by Polθi, we performed a CRISPR knockout screen which revealed loss of the TP53BP1/Shieldin pathway component

Indexed as

DNA Polymerase thetaProstatic NeoplasmsCell Line, TumorDNA Breaks, Double-StrandedDNA End-Joining RepairHumansMaleRadiation ToleranceDNA Polymerase theta

Identifiers

PMID42284420
PMCPMC13262640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.